19.06.2018
Arrowhead initiates coverage on Deinove in the United States
The American financial services and research provider firm has initiated coverage on Deinove’s stock with a valuation of up to €5.55 per...
Press releases
15.06.2018
DEINOVE: Successful capital increase of € 8.5 million
Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...
14.06.2018
DEINOVE announces today the launch of a capital increase through an accelerated book building
Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...
30.05.2018
DEINOVE and OLEOS expand their collaboration with the support of the Occitanie Region
A second cosmetic active ingredient will be developed as part of the collaboration between DEINOVE and Hallstar-Oléos. The Occitanie Region...
23.05.2018
General meeting of May 23: Shareholders approve the acquisition of MORPHOCHEM
The General Meeting approved the contribution in kind of the BIOVERTIS (parent company of MORPHOCHEM) shares and options and the issuance...
22.05.2018
COLOR2B project: confirmed progress and outlook
The selected producer strain shows performance comparable to petrochemical products on the market today. The tests continue to validate the...
16.04.2018
DEINOVE and GREENTECH announce the launch of HEBELYS®, the first cosmetic active ingredient resulting from their collaboration
HEBELYS ® is a natural active ingredient produced by the fermentation of Sphingomonas , a bacterium belonging to the DEINOVE proprietary...
13.04.2018
DEINOVE takes on a whole new dimension with the acquisition of MORPHOCHEM’s clinical-stage antibiotic compound
MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...
10.04.2018
DEINOVE introduces Phyt-n-Resist®, the first pure phytoene for skincare
Deinove scientific platform has designed an exclusive Deinococcus fermentation process to deliver the first pure Phytoene for application...
29.03.2018
2017: ambitions confirmed, milestones reached, and financial results in line with the development strategy
Acceleration of the Antibiotics program: €14.6m of funding by Bpifrance (including € 10.4m for the DEINOVE Group) and structuring of the...